USANA Health Sciences, Inc. (NYSE:USNA) Director Sells $21,918.00 in Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Peggie Pelosi sold 780 shares of the firm’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $28.10, for a total transaction of $21,918.00. Following the sale, the director now owns 3,395 shares in the company, valued at approximately $95,399.50. The trade was a 18.68 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

USANA Health Sciences Price Performance

Shares of USNA opened at $30.86 on Thursday. The firm has a 50-day moving average of $33.20 and a 200-day moving average of $36.34. USANA Health Sciences, Inc. has a one year low of $27.71 and a one year high of $50.32. The company has a market cap of $588.10 million, a PE ratio of 10.90, a price-to-earnings-growth ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 25th. The company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.49 by $0.15. The business had revenue of $213.61 million during the quarter, compared to the consensus estimate of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. Analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on USNA shares. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 14th. Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 18th. Finally, DA Davidson lowered their price target on shares of USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, February 27th.

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. R Squared Ltd bought a new stake in shares of USANA Health Sciences during the 4th quarter worth about $28,000. Safe Harbor Fiduciary LLC bought a new stake in shares of USANA Health Sciences during the 3rd quarter worth about $30,000. KBC Group NV boosted its holdings in USANA Health Sciences by 96.6% in the 3rd quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after purchasing an additional 519 shares during the period. KLP Kapitalforvaltning AS bought a new stake in USANA Health Sciences in the 4th quarter valued at about $83,000. Finally, Quantbot Technologies LP bought a new stake in USANA Health Sciences in the 4th quarter valued at about $132,000. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.